Regulatory Roundup: FDA Takes Action Against Drug Manufacturer and Distributor - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Takes Action Against Drug Manufacturer and Distributor

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has issued a consent decree of condemnation, forfeiture, and permanent injunction against H&P Industries, The Triad Group, and three individuals to prevent them from manufacturing and distributing products from their Wisconsin facility and other locations. “The Triad Group distributes and H&P Industries manufactures a variety of over-the-counter drug products including povidone-iodine and benzalkonium chloride antiseptic products, cough and cold products, nasal sprays, suppositories, medicated wipes, antifungal creams, and hemorrhoidal wipes,” according to the agency announcement. H&P had failed to comply with cGMPs as demonstrated in inspections conducted by FDA between 2009 and 2011, and has initiated five product recalls because of bacterial contamination since December 2010. Operations cannot be resumed until the companies prove to have an acceptable Quality Assurance and Quality Control program.

The agency also approved redesigned drug container label produced by Merck that address a new standardized format aimed at improving readability and understanding of product and strength differentiation, according to an FDA release. The company’s labeling project included revising 34 container labels for 16 solid oral drugs.

The International Conference on Harmonization steering committee and expert working groups held one of their twice-annual meetings last week in Cincinnati, Ohio. Summaries of the meeting are expected soon.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here